Amplifier Therapeutics
CompanySweden
Amplifier Therapeutics develops one asset, in phase 1 (ATX-304 in obesity). Mostly small molecule acting on AMPK signalling, lipid and ceramide metabolism and PRKAA1; based in Sweden.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 0
- Signals
Pipeline
1Activates the AMPK network, increasing glucose uptake and mitochondrial respiration to raise metabolic rate.
Phase 1, Small molecule, AMPK signalling, Lipid and ceramide metabolism, obesity, obesity associated diseases
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Signals1
- Similar companies6
Papers
Phase 1b Study of AMPK/Mitochondrial Activator ATX-304 in Prediabetic Obese Participants
ADA Scientific Sessions 2026 abstract, 5 Jun 2026